BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback